Nymox Pharmaceutical Corporation
NYMXF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $11 | $12 | $12 |
| Gross Profit | -$1 | -$11 | -$12 | -$12 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,279 | $3,983 | $3,761 | $6,646 |
| G&A Expenses | $0 | $0 | $2,879 | $5,846 |
| SG&A Expenses | $1,003 | $4,356 | $2,879 | $5,846 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,282 | $8,339 | $6,640 | $12,492 |
| Operating Income | -$4,283 | -$8,350 | -$6,652 | -$12,504 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$209 | -$494 | $76 | -$33 |
| Pre-Tax Income | -$4,492 | -$8,844 | -$6,576 | -$12,537 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,492 | -$8,844 | -$6,576 | -$12,537 |
| % Margin | – | – | – | – |
| EPS | -0.048 | -0.097 | -0.074 | -0.15 |
| % Growth | 50.3% | -31.1% | 50.9% | – |
| EPS Diluted | -0.048 | -0.097 | -0.074 | -0.15 |
| Weighted Avg Shares Out | 93,671 | 91,687 | 89,383 | 81,976 |
| Weighted Avg Shares Out Dil | 93,671 | 91,687 | 89,383 | 81,976 |
| Supplemental Information | – | – | – | – |
| Interest Income | $17 | $6 | $1 | $8 |
| Interest Expense | $226 | $61 | $43 | $39 |
| Depreciation & Amortization | $1 | $11 | $12 | $12 |
| EBITDA | -$4,265 | -$8,772 | -$6,521 | -$12,492 |
| % Margin | – | – | – | – |